Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 49Gastrointestinal 38CNS 32Breast 28Lymphoid 27Thoracic 19Sarcoma 18Gynecologic 18Endocrine 13Head & Neck 11Tumor-Agnostic 8Plasma cell 7Dermatologic 6Other hematologic neoplasm 5NET 5Myeloid 5Other solid neoplasm 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Magnetic Resonance Spectroscopy × Other solid neoplasm × Clear all
NCT06351371 2026-05-28

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡